NEUP Earnings — Neuphoria Therapeutics Inc. Common Stock Post-ER Performance | BigEarnings
NEUP — Neuphoria Therapeutics Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$4.57
Market Cap$24.7M
P/E—
52W Range$3.65 – $21.40
Next Earnings2026-09-28
About Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
